Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT ID: NCT00538902

Last Updated: 2011-04-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 302 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-08-31
• Study Completion Date: 2009-12-31

Brief Summary

A study to assess the safety and efficacy of adalimumab administered as a subcutaneous injection in adult Chinese subjects with rheumatoid arthritis and treated with methotrexate

Detailed Description

This was a multi-center, Phase 2/3, randomized, double-blind (DB), parallel group, placebo controlled, safety and efficacy study in adult Chinese RA subjects. The duration of the study was approximately 116 weeks. This included a 4-week (28 days) Screening period, a 12-week Double-Blind (DB) period, a 90-week Open-Label (OL) Period, and a 10-week (70 days) Follow-up period. The 70-day Safety Follow-up period was initiated after the last dose of study medication.

During the DB period, 302 Chinese subjects with RA and concomitantly treated with MTX were enrolled at 11 clinical sites located throughout China. Subjects were randomly assigned to one of the three treatment groups in a 2:2:1 ratio: 80 mg adalimumab, 40 mg adalimumab, or placebo. From Week 0 to Week 10, subjects received blinded study drug. Subjects who successfully participated and completed Week 12 of the DB portion of the study participated in the OL period. All subjects in the OL period received adalimumab 40 mg. Throughout the study, the study drug was administered subcutaneously (SC) every other week (eow).

Subjects that completed the Week 24 visit, prior to the approval of Protocol Amendment 1, had 70 days from the last dose of study drug to re-enter the study. The Investigator confirmed that the subject did not develop any of the exclusion criteria and completed the procedures defined by the OL Screening visit.

Results through Week 24 of this study were presented in the regulatory dossier for the marketing authorization application of Humira in China, fulfilling the requirement for clinical data in Chinese patients. However, in order to continue to provide treatment to patients who responded well to adalimumab, subjects had the option to continue in the OL extension of this study until Week 92.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Placebo

Placebo administered subcutaneously every other week

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

Adalimumab 80 mg

Adalimumab 80 mg administered subcutaneously every other week

Group Type: EXPERIMENTAL

Adalimumab 80 mg

Intervention Type: BIOLOGICAL

Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

Adalimumab 40 mg

Adalimumab 40 mg administered subcutaneously every other week

Group Type: EXPERIMENTAL

Adalimumab 40 mg

Intervention Type: BIOLOGICAL

Adalimumab 40 mg administered subcutaneously every other week for 104 weeks

Interventions

Placebo

Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

Intervention Type: BIOLOGICAL

Adalimumab 80 mg

Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

Intervention Type: BIOLOGICAL

Adalimumab 40 mg

Adalimumab 40 mg administered subcutaneously every other week for 104 weeks

Intervention Type: BIOLOGICAL

Other Intervention Names

Humira; Humira

Eligibility Criteria

Inclusion Criteria

• Met ACR criteria for diagnosis of active rheumatoid arthritis (RA) and have had at both the Screening visit and Week 0 visit at least four swollen joints (out of 66 assessed) and at least six tender joints(out of 68 assessed)
• Subjects must have failed prior treatment with one or more disease-modifying antirheumatic drugs (DMARDs)
• DMARDs (other than methotrexate [MTX]) must have been discontinued for >= 28 days or at least 5 half-lives, whichever is greater, before the Week 0 visit
• Traditional Chinese Medicines must have been discontinued for >= 28 days before the Week 0 visit
• Subjects must have received at least three months of treatment with MTX (minimum 7.5 mg/week) and remained on a stable dose of MTX for >= 28 days prior to the Screening visit
• Glucocorticoids equivalent to <= 10 mg of prednisone and prednisone equivalent must have remained unchanged for at least 28 days prior to the Week 0 visit
• Must have been able and willing to give written informed consent and to comply with the requirements of this study protocol

Exclusion Criteria

• A history of, or current, acute inflammatory joint disease of different origin (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus, fibromyalgia or any arthritide with onset prior to age 16 years
• Wheelchair-bound or bedridden
• Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit
• Intra-articular, intramuscular or intravenous administration of corticosteroids within 28 days prior to the Screening visit
• Prior treatment with any TNF antagonist, including adalimumab
• Subject considered by the investigator, for any reason, to be an unsuitable candidate
• Female subject who is pregnant or breast-feeding or considering becoming pregnant

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: lead

Responsible Party

Abbott

Principal Investigators

Laura Redden, MD, PhD

Role: STUDY_DIRECTOR

Abbott

Locations

Site Reference ID/Investigator# 6243

Guangzhou, , China

Site Reference ID/Investigator# 6247

Guangzhou, , China

Site Reference ID/Investigator# 6262

Harbin, , China

Site Reference ID/Investigator# 6248

Hepingjiebeikou, , China

Site Reference ID/Investigator# 6250

Shanghai, , China

Site Reference ID/Investigator# 6828

Shanghai, , China

Site Reference ID/Investigator# 6333

Shanghai, , China

Site Reference ID/Investigator# 6264

Xi'an, , China

Site Reference ID/Investigator# 6259

Hefei, AN, China

Site Reference ID/Investigator# 6266

Beijing, , China

Site Reference ID/Investigator# 6241

Beijing, , China

Countries

China

References

Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.

Reference Type: DERIVED

PMID: 27338778 (View on PubMed)

Other Identifiers

M04-705

Identifier Type: -

Identifier Source: org_study_id